Human 5-hydroxytryptamine1B (5-HT1B; also designated 5-HT1D beta) receptors and 5-HT1D (also designated 5-HT1D alpha) receptors are distinct molecular entities which mediate serotonergic neurotransmission. The often confusing variability in nomenclature for these two G protein-coupled receptors derives from a preliminary observation that these receptors display nearly indistinguishable pharmacological properties. The present study analyzed a series of 21 drugs, 8 of which were found to be at least an order of magnitude more potent at 5-HT1D than 5-HT1B receptors. These data provide pharmacological evidence that human 5-HT1B and 5-HT1D receptors are distinct molecular entities which represent independent targets for future drug development. Furthermore, these data indicate that a number of selective pharmacological agents already exist and can be used to analyze the functional roles of 5-HT1B and 5-HT1D receptors.
No takes yet. Share an insight, caveat, or question.
Stephen J. Peroutka (1994) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: